Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Sophie Miriam Lanzkron, MD
Healthcare Provider Director of Sickle Cell Center for Adults
The Johns Hopkins Hospital
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, Maryland, United States
Dr. Sophie Lanzkron is an associate professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hematology and sickle cell disease. Dr. Lanzkron is director of the Sickle Cell Center for Adults at Johns Hopkins. Dr. Lanzkron received her undergraduate degree in biology from Brandeis University. She earned her M.D. from Albert Einstein College of Medicine. She completed her residency at the University of Maryland Medical Center and performed her fellowship in hematology at Johns Hopkins. She joined the faculty of Johns Hopkins in 2000.
Dr. Lanzkron’s major clinical research involves the study of sickle cell disease. Her primary research interest is to understand the barriers to care for adults with sickle cell disease. In 1998, the FDA approved the use of hydroxyurea to treat patients with sickle cell disease. This approval was based on a large clinical trial centered at Johns Hopkins. The use of hydroxyurea was predicted to decrease hospitalizations and the costs of care for those with sickle cell disease. Dr. Lanzkron’s research has shown that despite the approval of hydroxyurea, the costs of caring for patients with sickle cell disease have increased significantly over the last seven years. Research is ongoing to identify the factors that limit access to care for this population.
Representative Publications:
Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease
Related Content
-
Simone C. Eastman Uwan, MDDr. Simone Eastman Uwan was born in Guya...
-
Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role ...Despite its rarity in the United States,...
-
Jeff Glassberg, MDDr. Jeffrey Glassberg obtained his MD an...
-
Sickle Cell Disease Association of America – Mobile Chapter, Inc.The Sickle Cell Disease Association of A...
-
Dana-Farber/Boston Children’s Cancer and Blood Disorders CenterSpecialists in the Sickle Cell Disease P...
-
GBT launches ACCEL grants program to improve access to care for people with Sickle cell diseaseGlobal Blood Therapeutics, Inc. (GBT) to...
-
Patients With Sickle Cell Disease may Have Lower Risk for C. DifficileFindings from a retrospective cohort stu...